| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Sabina Signoretti | Q90424571 |
| Meredith M Regan | Q99564359 | ||
| P2093 | author name string | Michael B Atkins | |
| James W Mier | |||
| Daniel Cho | |||
| P433 | issue | 2 Pt 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | sirolimus | Q32089 |
| P304 | page(s) | 758s-763s | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer | |
| P478 | volume | 13 |
| Q38041260 | A drug safety evaluation of everolimus in kidney transplantation |
| Q34479371 | AMPK as a therapeutic target in renal cell carcinoma |
| Q38068519 | Adverse events associated with mTOR inhibitors |
| Q37875792 | Antiangiogenic treatments and mechanisms of action in renal cell carcinoma |
| Q37145171 | Carbonic anhydrase IX as a predictive biomarker of response to kidney cancer therapy |
| Q38924677 | Chronic oxidative stress leads to malignant transformation along with acquisition of stem cell characteristics, and epithelial to mesenchymal transition in human renal epithelial cells |
| Q35931293 | Complex cellular functions of the von Hippel-Lindau tumor suppressor gene: insights from model organisms |
| Q34536470 | Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma. |
| Q26860172 | Differentiating mTOR inhibitors in renal cell carcinoma |
| Q36302824 | Effect of everolimus on the immunomodulation of the human neutrophil inflammatory response and activation |
| Q37965053 | Evaluation of treatment response in patients with metastatic renal cell carcinoma: role of state-of-the-art cross-sectional imaging |
| Q37508003 | Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma |
| Q37236275 | FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer |
| Q39901893 | Induction of iodide uptake in transformed thyrocytes: a compound screening in cell lines. |
| Q34821300 | Influence of proliferation signal inhibitors on vascular endothelial growth factor production in heart transplant recipients - preliminary report |
| Q40817688 | Interferon-α enhances the susceptibility of renal cell carcinoma to rapamycin by suppressing mTOR activity |
| Q36976986 | Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial |
| Q37209537 | Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC. |
| Q39233604 | Mechanistic target of rapamycin small interfering RNA and rapamycin synergistically inhibit tumour growth in a mouse xenograft model of human oesophageal carcinoma |
| Q34159241 | Metformin and cancer |
| Q42650839 | Methods to identify molecular expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitors |
| Q37942072 | Molecular aspects of renal cell carcinoma: a review |
| Q33915992 | Multiple roles and therapeutic implications of Akt signaling in cancer. |
| Q37223221 | Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients |
| Q37016007 | PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma |
| Q34760312 | Phospholipase D activates HIF-1-VEGF pathway via phosphatidic acid |
| Q36214648 | Piperlongumine and its analogs down-regulate expression of c-Met in renal cell carcinoma |
| Q33317794 | Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies |
| Q38263467 | RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid |
| Q38686817 | Rap2B promotes angiogenesis via PI3K/AKT/VEGF signaling pathway in human renal cell carcinoma |
| Q34064359 | Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma |
| Q38569361 | Role of the translational repressor 4E-BP1 in the regulation of p21(Waf1/Cip1) expression by retinoids |
| Q34757109 | Statin use is associated with improved survival in patients undergoing surgery for renal cell carcinoma |
| Q28245467 | Sunitinib in solid tumors |
| Q37803147 | Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements |
| Q37575635 | Systemic therapy of kidney cancer: tyrosine kinase inhibitors, antiangiogenesis or IL-2? |
| Q43121227 | Targeted therapies for renal cell carcinoma: more gains from using them again. |
| Q37505000 | Targeted therapy for Kaposi sarcoma |
| Q36871985 | Targeting cancer stem cells. |
| Q39747275 | Targeting of VEGF-dependent transendothelial migration of cancer cells by bevacizumab. |
| Q37342956 | The impact of metformin use on recurrence and cancer-specific survival in clinically localized high-risk renal cell carcinoma |
| Q34235680 | The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy |
| Q38051247 | The role of mammalian target of rapamycin (mTOR) inhibition in the treatment of advanced breast cancer. |
| Q37366977 | The soluble Decoy Receptor 3 is regulated by a PI3K-dependent mechanism and promotes migration and invasion in renal cell carcinoma |
| Q37272653 | The von Hippel-Lindau gene: turning discovery into therapy |
| Q37259415 | Tissue biomarkers in renal cell carcinoma: issues and solutions |
| Q36982059 | Tissue-based research in kidney cancer: current challenges and future directions |
| Q37863582 | Treatment of metastatic renal cell carcinoma and renal pelvic cancer |
| Q36932510 | Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. |
| Q33699582 | Treatment-related mortality with everolimus in cancer patients. |
| Q85849574 | Tubulocystic renal cell carcinoma: is there a rational reason for targeted therapy using angiogenic inhibition? Analysis of seven cases |
| Q89651597 | Turning liabilities into opportunities: Off-target based drug repurposing in cancer |
| Q37765586 | Understanding the molecular genetics of renal cell neoplasia: implications for diagnosis, prognosis and therapy |
| Q37774569 | Using Molecular Biology to Develop Drugs for Renal Cell Carcinoma |
| Q37393004 | VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy |
| Q38962103 | mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions |
Search more.